MX2021012394A - Eficacia profilactica de los agonistas del receptor de serotonina 4 contra el estres. - Google Patents
Eficacia profilactica de los agonistas del receptor de serotonina 4 contra el estres.Info
- Publication number
- MX2021012394A MX2021012394A MX2021012394A MX2021012394A MX2021012394A MX 2021012394 A MX2021012394 A MX 2021012394A MX 2021012394 A MX2021012394 A MX 2021012394A MX 2021012394 A MX2021012394 A MX 2021012394A MX 2021012394 A MX2021012394 A MX 2021012394A
- Authority
- MX
- Mexico
- Prior art keywords
- serotonin
- receptor agonists
- stress
- against stress
- prophylactic efficacy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831517P | 2019-04-09 | 2019-04-09 | |
| US201962857075P | 2019-06-04 | 2019-06-04 | |
| US201962910859P | 2019-10-04 | 2019-10-04 | |
| PCT/US2020/027321 WO2020210393A1 (en) | 2019-04-09 | 2020-04-08 | Prophylactic efficacy of serotonin 4 receptor agonists against stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021012394A true MX2021012394A (es) | 2022-01-19 |
Family
ID=72750568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021012394A MX2021012394A (es) | 2019-04-09 | 2020-04-08 | Eficacia profilactica de los agonistas del receptor de serotonina 4 contra el estres. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220031684A1 (enExample) |
| EP (1) | EP3952852B1 (enExample) |
| JP (1) | JP7683882B2 (enExample) |
| CN (1) | CN113924087A (enExample) |
| AU (1) | AU2020271839B2 (enExample) |
| CA (1) | CA3136328A1 (enExample) |
| MX (1) | MX2021012394A (enExample) |
| WO (1) | WO2020210393A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7821116B2 (ja) * | 2020-04-07 | 2026-02-26 | ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク | ストレス誘導性恐怖、うつ様行動および不安様行動の予防のための組成物および方法 |
| EP4577305A4 (en) * | 2022-08-25 | 2026-07-29 | Univ Columbia | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ANOTHER NEURODEGENERATIVE DISEASE |
| CN118105081B (zh) * | 2024-03-04 | 2025-02-11 | 天津大学 | 一种情绪状态与神经电生理状态调节装置、验证系统及方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2846559B1 (fr) * | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US20090170899A1 (en) | 2004-09-14 | 2009-07-02 | Guy Debonnel | Stimulators of 5-HT4 receptors and uses thereof |
| US9642862B2 (en) | 2010-11-18 | 2017-05-09 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
| EP3377050A4 (en) | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
-
2020
- 2020-04-08 JP JP2021560628A patent/JP7683882B2/ja active Active
- 2020-04-08 CN CN202080042252.4A patent/CN113924087A/zh active Pending
- 2020-04-08 MX MX2021012394A patent/MX2021012394A/es unknown
- 2020-04-08 WO PCT/US2020/027321 patent/WO2020210393A1/en not_active Ceased
- 2020-04-08 CA CA3136328A patent/CA3136328A1/en active Pending
- 2020-04-08 EP EP20786878.7A patent/EP3952852B1/en active Active
- 2020-04-08 AU AU2020271839A patent/AU2020271839B2/en active Active
-
2021
- 2021-10-05 US US17/494,218 patent/US20220031684A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022527865A (ja) | 2022-06-06 |
| EP3952852B1 (en) | 2026-07-22 |
| AU2020271839B2 (en) | 2025-04-24 |
| WO2020210393A1 (en) | 2020-10-15 |
| CA3136328A1 (en) | 2020-10-15 |
| EP3952852A4 (en) | 2023-01-04 |
| AU2020271839A1 (en) | 2021-11-04 |
| CN113924087A (zh) | 2022-01-11 |
| US20220031684A1 (en) | 2022-02-03 |
| JP7683882B2 (ja) | 2025-05-27 |
| EP3952852A1 (en) | 2022-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002526A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares (divisional de solicitud n°2485-2015) | |
| MX2024010140A (es) | Nuevos metodos. | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| MX2020001732A (es) | Tratamiento de las afecciones del sistema nervioso central. | |
| MX2024001205A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso. | |
| MX2021004708A (es) | Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares. | |
| MX2022010274A (es) | Uso de dexmedetomidina sublingual para el tratamiento de la agitacion. | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| MX2021000376A (es) | Composiciones tópicas para el alivio del dolor. | |
| EA200901339A1 (ru) | Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| EP4324454A3 (en) | Cross-linking agents and associated methods | |
| MX2018013663A (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
| CL2023003893A1 (es) | Semaglutida para el tratamiento de esteatohepatitis no alcohólica. | |
| MX393900B (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| PH12019550199A1 (en) | Methods of preventing or treating ophthalmic diseases | |
| AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| EA201992389A1 (ru) | Замещенные n-арилэтил-2-аминохинолин-4-карбоксамиды и их применение | |
| AR114306A1 (es) | Tratamiento y prevención de trastornos del sueño |